Recent Postings to

Worst Pills, Best Pills Newsletter Articles

  View the entire May 2019 issue in PDF format

  • Review of Testosterone Products
    (May 2019)
    Approximately 10 years ago, testosterone makers launched a massive direct-to-consumer advertising campaign to promote the use of testosterone for normal age-related declines in testosterone in men. Learn why such use of testosterone can be dangerous without providing any proven benefit.
  • Beware of Companies Hawking Snake Oil for Alzheimer’s Disease
    (May 2019)
    The FDA’s recent warning about a dozen companies that marketed illegal products purported to treat or prevent Alzheimer’s disease highlights the importance of ignoring advertisements promoting miracle cures for serious diseases.
  • Indacaterol (ARCAPTA NEOHALER): The Wrong Choice for COPD
    (May 2019)
    In this article, we explain why the FDA should not have approved indacaterol, a long-acting inhaled bronchodilator, for long-term treatment of COPD without first requiring further clinical trials testing lower doses of the drug than the currently approved dose.
  • Colchicine Interactions with Other Drugs Can Be Life-Threatening
    (May 2019)
    Read about the many prescription medications that can interact in dangerous ways with colchicine, a commonly used drug for treatment of acute gout attacks.
  • Medications That Induce Breast Enlargement in Men
    (May 2019)
    For men, abnormally large breasts can be distressing and embarrassing. Find out about the numerous drugs that can cause breast enlargement in men.

  View the entire April 2019 issue in PDF format

  View the entire March 2019 issue in PDF format

  • Study Reveals Increased Risk of Bleeding, Stroke from Combined Use of Oral Blood Thinners and NSAIDs
    (March 2019)
    Millions of Americans take anticoagulants on a long-term basis to prevent the formation of potentially harmful clots. Learn why such patients should avoid using nonsteroidal anti-inflammatory drugs.
  • Caving To Industry, FDA Kills Proposed Safety Rule on Generic Drug Labeling
    (March 2019)
    In his editor’s column, Dr. Michael Carome laments the FDA’s troubling decision to withdraw a proposed rule that would have allowed generic drug companies to promptly update safety warnings in their product labels.
  • Potentially Dangerous Lithium Drug Interactions
    (March 2019)
    Read about the many prescription medications that can interact in dangerous ways with lithium, the drug of choice for treating bipolar disorder, also known as manic depression.
  • Drug-Induced Restless Legs Syndrome
    (March 2019)
    Restless legs syndrome is a common neurological movement and sensory disorder that affects 5 to 10 percent of the population. In this article, we identify some of the many drugs that can cause or worsen this disorder.
  • Review of the Synthetic Human Growth Hormone Drug Somatropin
    (March 2019)
    Somatropin was first approved by the FDA in 1987 for the treatment of short stature in children with growth hormone (GH) deficiency. Find out why we recommend not using somatropin in children with short stature who have normal GH levels; people who develop GH deficiency in adulthood; or in healthy individuals as an anti-aging agent, to improve athletic performance or for body-building.

Additional Information from Public Citizen

Copyright © 2019 Public Citizen's Health Research Group. All rights reserved.